Novartis Q1 Sales Decline Reflects Industry Challenges with Generics and Patent Expirations
Novartis reported a 12% drop in Q1 profits to $4.9 billion and a 1% decline in net sales to $13.1 billion, driven by generic competition and patent expirations. The company expects continued challenges in the first half of 2026, with Q2 sales projected to decline by low single digits and full-year net sales growth expected in the low single-digit range.
Tickers: $NVS
Topics: earnings miss generic drugs M&A patent cliff pharmaceutical industry sales decline